Tumors That Acquire Resistance to Low-Dose Metronomic Cyclophosphamide Retain Sensitivity to Maximum Tolerated Dose Cyclophosphamide

Tumors That Acquire Resistance to Low-Dose Metronomic Cyclophosphamide Retain Sensitivity to Maximum Tolerated Dose Cyclophosphamide

Low-dose metronomic (LDM) chemotherapy is emerging as an alternative or supplemental dosing strategy to conventional maximum tolerated dose (MTD) chemotherapy. It is characterized primarily, but not exclusively, by antiangiogenic mechanisms of action and the absence of high-grade adverse effects co...

Full description

Bibliographic Details
Main Authors:	Urban Emmenegger, Giulio Francia, Annabelle Chow, Yuval Shaked, Andrew Kouri, Shan Man, Robert S. Kerbel
Format:	Article
Language:	English
Published:	Elsevier 2011-01-01
Series:	Neoplasia: An International Journal for Oncology Research
Online Access:	http://www.sciencedirect.com/science/article/pii/S1476558611801107

Similar Items

VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment
by: Skowronski Karolina, et al.
Published: (2010-12-01)

Bevacizumab with metronomic chemotherapy of low-dose oral cyclophosphamide in recurrent cervical cancer: Four cases
by: Rose Isono-Nakata, et al.
Published: (2018-05-01)

Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers
by: Luana Schito, et al.
Published: (2020-09-01)

A phase II study of high-dose celecoxib and metronomic 'low-dose' cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma
by: Naser Abd El Bary, et al.
Published: (2010-01-01)

Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial
by: Diane Pannier, et al.
Published: (2018-07-01)

Metronomic Chemotherapy with Cyclophosphamide and Piroxicam in Dogs with Malignant Tumors
by: Yung-Ching Chang, et al.
Published: (2019)

Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion.
by: Raquel Muñoz, et al.
Published: (2019-01-01)

Impact of Metronomic UFT/Cyclophosphamide Chemotherapy and Antiangiogenic Drug Assessed in a New Preclinical Model of Locally Advanced Orthotopic Hepatocellular Carcinoma
by: Terence C. Tang, et al.
Published: (2010-03-01)

High Dose Cyclophosphamide Treatment for Autoimmune Disorders
by: Robert A. Brodsky
Published: (2002-01-01)

Hyponatremia induced by high-dose cyclophosphamide therapy: a retrospective cohort study Cyclophosphamide and Hyponatremia.
by: Belen Maria Bonella, et al.
Published: (2017-09-01)

Metronomic cyclophosphamide with bevacizumab provides disease stabilization in patients with advanced uterine cancer
by: Ioannis Alagkiozidis, et al.
Published: (2015-04-01)

A Comprehensive Gene Expression Analysis of Resistance Formation upon Metronomic Cyclophosphamide Therapy
by: Rebekka Kubisch, et al.
Published: (2013-02-01)

Development of a Resistance-like Phenotype to Sorafenib by Human Hepatocellular Carcinoma Cells Is Reversible and Can Be Delayed by Metronomic UFT Chemotherapy
by: Terence C. Tang, et al.
Published: (2010-11-01)

Oral etoposide and cyclophosphamide: A low-cost palliative metronomic chemotherapy in advanced pediatric cancers
by: Kiran Kumar, et al.
Published: (2020-01-01)

Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer
by: Vizza Enrico, et al.
Published: (2007-04-01)

Cancer Therapy with Metronomically Scheduled Cyclophosphamide: Experimental Modalities within GDEPT and Tumor Escape Mechanisms
by: Guenther, Michael
Published: (2007)

Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
by: Orlando Laura, et al.
Published: (2006-09-01)

Toxic effects of different doses of cyclophosphamide on the reproductive parameters of male mice
by: Tatiane Yumi Nakamura Kanno, et al.
Published: (2009-06-01)

Cyclophosphamide and the taste system: Effects of dose fractionation and amifostine on taste cell renewal.
by: Eugene R Delay, et al.
Published: (2019-01-01)

Efficacy of high-dose methylprednisolone and cyclophosphamide in childhood-onset systemic lupus erythematosus
by: Putu Ayunda Trisnia, et al.
Published: (2020-04-01)

Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway
by: Hui Zhong, et al.
Published: (2020-01-01)

Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity
by: Joris D. Veltman, et al.
Published: (2010-01-01)

Peyronie′s disease treated with oral weekly dexamethasone and continuous low-dose cyclophosphamide
by: Ramji Gupta, et al.
Published: (2014-01-01)

Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer
by: Jorge L. Soriano, et al.
Published: (2011-01-01)

Haploidentical stem cell transplant with post-transplantation cyclophosphamide and mini-dose methotrexate in children
by: Diego Medina, et al.
Published: (2020-12-01)

Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide
by: Ashley Munchel, et al.
Published: (2011-06-01)

Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag
by: Faiz Anwer, et al.
Published: (2015-01-01)

Gonadal status following bone marrow transplantation with low dose busulfan-cyclophosphamide regimen
by: Mohsen Khosh niat Nikoo, et al.
Published: (2006-02-01)

Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag
by: Anwer, Faiz, et al.
Published: (2015)

Low-Dose Cyclophosphamide Induces Nerve Injury and Functional Overactivity in the Urinary Bladder of Rats
by: Rui Wang, et al.
Published: (2021-10-01)

The efficiency and side-effects of low-dose Fludarabine-Cyclophosphamide in the treatment of chronic lymphocytic leukemia
by: Murat Albayrak, et al.
Published: (2010-05-01)

Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens
by: Anup Tank, et al.
Published: (2020-03-01)

Mechanisms of Fatal Cardiotoxicity following High-Dose Cyclophosphamide Therapy and a Method for Its Prevention.
by: Takuro Nishikawa, et al.
Published: (2015-01-01)

Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma
by: Farzaneh Ashrafi, et al.
Published: (2020-01-01)

Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
by: Hamid Reza Mirzaei, et al.
Published: (2013-01-01)

Cyclophosphamide-Induced Cardiomyopathy
by: Sumandeep Dhesi MD, et al.
Published: (2013-01-01)

Clinical pharmacokinetics of cyclophosphamide
by: Juma, F. D.
Published: (1980)

Vinorelbine-Cyclophosphamide compared to cyclophosphamide in peripheral blood stem cell mobilization for multiple myeloma
by: Sanjay de Mel, et al.
Published: (2018-12-01)

Benzyl alcohol-benzyl benzoate clearing reveals the dose-dependent effect of cyclophosphamide on follicle damage in mice
by: Qi-Wang Lin, et al.
Published: (2020-01-01)

Cyclophosphamide alters the gene expression profile in patients treated with high doses prior to stem cell transplantation.
by: Ibrahim El-Serafi, et al.
Published: (2014-01-01)

Cannot write session to /tmp/vufind_sessions/sess_vd14ck1s2d1fe5sfa9amq9niui